The safety of Canada’s blood supply is under intense scrutiny following the deaths of two donors at private plasma collection centers. The fatalities, occurring between late 2025 and early 2026, have reignited a fierce national debate over the “creeping privatization” of Canada’s healthcare system and the oversight of international pharmaceutical giants.
Health Canada confirmed it received reports of “fatal adverse reactions” involving donors at facilities operated by Grifols, a Spanish healthcare multinational. While plasma donation is generally considered a safe procedure, these incidents have raised “alarm bells” among safety advocates and federal inspectors.
Timeline of a Developing Crisis
The identities of the deceased have largely been withheld by authorities, though community members have begun to speak out:
-
October 25, 2025: Rodiyat Alabede, a 22-year-old international student and aspiring social worker, died after donating at a Winnipeg clinic. Friends describe her as a “devoted” individual who moved to Canada to help others.
-
January 2026: A second donor died under similar circumstances of “distress” at a different Winnipeg location.
-
March 2026: Reports surface that provincial health agencies were only recently notified of the deaths, despite the first occurring nearly six months ago.
Federal Inspections Reveal “Troubling” Deficiencies
Recent Health Canada inspection reports obtained by the media paint a concerning picture of the conditions inside some Grifols-run facilities. One site in Saskatchewan was recently rated non-compliant after inspectors identified 11 distinct deficiencies, including:
-
Improper Screening: Failure to accurately assess whether a donor was suitable for the procedure.
-
Equipment Negligence: Insufficient validation, calibration, and cleaning of critical machinery.
-
Poor Record Keeping: Inaccurate or incomplete data, making it difficult to track donor safety.
Of all documented instances of non-compliance in Canadian blood inspections since 2016, Grifols-operated facilities account for 50% of the cases.
“When I learned of a second death—in the same city—alarm bells started going off,” said Curtis Brandell, president of the British Columbia chapter of the Canadian Hemophilia Society. “We were promised transparency. That’s not what we’re getting.”
The Privatization Debate: Ethics vs. Necessity
Canada has long struggled to meet its domestic demand for plasma, often relying on imports from the United States. To bridge this gap, the country has increasingly allowed private companies like Grifols to offer paid incentives—up to $100 per donation plus “Super Hero” cash bonuses for frequent donors.
Critics argue this model mirrors the “slow collapse” of a system once considered the envy of the world. They point to the 1980s Tainted Blood Scandal, where thousands were infected with HIV and Hepatitis C, as a haunting reminder of what happens when profit is prioritized over public safety.
Legal Challenges and Corporate Response
The tragedy in Winnipeg is not the only shadow looming over Grifols. A separate lawsuit alleges a “machine error” at one of their facilities caused permanent kidney damage to a donor by returning “broken” red blood cells to his body.
In response to the deaths and inspection failures, Grifols stated:
-
There is “no reason to believe” a correlation exists between the deaths and the donation process.
-
The company is implementing “detailed action plans” to address the non-compliance ratings.
-
All donors undergo extensive health evaluations before being cleared to donate.
As Health Canada continues its investigation, the families of the deceased and blood safety advocates are calling for a return to the voluntary, non-commercial model recommended by the Royal Commission of Inquiry to ensure such a tragedy never happens again.
